SG11202012930RA - Triazole glycolate oxidase inhibitors - Google Patents
Triazole glycolate oxidase inhibitorsInfo
- Publication number
- SG11202012930RA SG11202012930RA SG11202012930RA SG11202012930RA SG11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA SG 11202012930R A SG11202012930R A SG 11202012930RA
- Authority
- SG
- Singapore
- Prior art keywords
- triazole
- oxidase inhibitors
- glycolate oxidase
- glycolate
- inhibitors
- Prior art date
Links
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title 1
- 108010062584 glycollate oxidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US201962827573P | 2019-04-01 | 2019-04-01 | |
| PCT/US2019/040690 WO2020010309A1 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012930RA true SG11202012930RA (en) | 2021-01-28 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012930RA SG11202012930RA (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11401246B2 (es) |
| EP (1) | EP3817816A1 (es) |
| JP (1) | JP7348705B2 (es) |
| KR (1) | KR20210041564A (es) |
| CN (1) | CN112399873A (es) |
| AU (1) | AU2019297523A1 (es) |
| BR (1) | BR112021000050A2 (es) |
| CA (1) | CA3104529A1 (es) |
| CO (1) | CO2021001277A2 (es) |
| IL (1) | IL279952A (es) |
| MX (1) | MX2021000051A (es) |
| PE (1) | PE20210859A1 (es) |
| SG (1) | SG11202012930RA (es) |
| WO (1) | WO2020010309A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020010309A1 (en) | 2018-07-06 | 2020-01-09 | Orfan Biotech Inc. | Triazole glycolate oxidase inhibitors |
| MX2022005065A (es) | 2019-11-01 | 2022-08-17 | Gyanrx Sciences Inc | Compuestos heterocíclicos de carboxilato como inhibidores de glicolato oxidasa. |
| WO2021142155A1 (en) * | 2020-01-08 | 2021-07-15 | Orfan Biotech Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| TW202339727A (zh) * | 2021-10-11 | 2023-10-16 | 美商坎特羅治療股份有限公司 | 使用１ｈ－１，２，３－三唑－４－羧酸之治療方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (ja) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | ベンゾピラノトリアゾ−ル誘導体 |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| ES2369835T3 (es) | 2003-11-19 | 2011-12-07 | Array Biopharma, Inc. | Inhibidores bicíclicos de mek y métodos de síntesis de los mismos. |
| AU2005286731A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| AR089682A1 (es) | 2012-01-10 | 2014-09-10 | Hoffmann La Roche | Compuestos de piridazina-amida |
| JP5455279B1 (ja) | 2012-10-25 | 2014-03-26 | アサヒグループホールディングス株式会社 | ラテックスの増産方法 |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (fr) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | Methode et composition pour ameliorer la productivite de plantes non legumineuses |
| JP5866035B1 (ja) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | 有効分げつ促進方法 |
| WO2016148193A1 (ja) | 2015-03-19 | 2016-09-22 | 興人ライフサイエンス株式会社 | 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物 |
| US20200262794A1 (en) * | 2015-12-07 | 2020-08-20 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| SG11202005807QA (en) * | 2017-12-29 | 2020-07-29 | Biomarin Pharm Inc | Glycolate oxidase inhibitors for the treatment of disease |
| US20210171503A1 (en) | 2017-12-29 | 2021-06-10 | Orfan Biotech Inc. | Glycolate oxidase inhibitors and use thereof |
| WO2019165159A1 (en) | 2018-02-23 | 2019-08-29 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| WO2020010309A1 (en) | 2018-07-06 | 2020-01-09 | Orfan Biotech Inc. | Triazole glycolate oxidase inhibitors |
| JP2022536969A (ja) | 2019-06-19 | 2022-08-22 | ビオマリン プハルマセウトイカル インコーポレイテッド | 疾患の治療のためのグルコール酸オキシダーゼ阻害剤 |
-
2019
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en active Application Filing
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/es unknown
- 2019-07-05 CA CA3104529A patent/CA3104529A1/en active Pending
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/es unknown
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/pt unknown
- 2019-07-05 AU AU2019297523A patent/AU2019297523A1/en active Pending
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/ja active Active
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
- 2019-07-05 KR KR1020217003486A patent/KR20210041564A/ko unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873A/zh active Pending
-
2021
- 2021-01-04 IL IL279952A patent/IL279952A/en unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/es unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020010309A1 (en) | 2020-01-09 |
| CN112399873A (zh) | 2021-02-23 |
| MX2021000051A (es) | 2021-03-25 |
| IL279952A (en) | 2021-03-01 |
| CA3104529A1 (en) | 2020-01-09 |
| JP2021530560A (ja) | 2021-11-11 |
| BR112021000050A2 (pt) | 2021-04-06 |
| JP7348705B2 (ja) | 2023-09-21 |
| CO2021001277A2 (es) | 2021-04-30 |
| US20210403439A1 (en) | 2021-12-30 |
| KR20210041564A (ko) | 2021-04-15 |
| US11401246B2 (en) | 2022-08-02 |
| PE20210859A1 (es) | 2021-05-18 |
| US20230143491A1 (en) | 2023-05-11 |
| AU2019297523A1 (en) | 2021-02-25 |
| EP3817816A1 (en) | 2021-05-12 |
| WO2020010309A9 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| IL290341A (en) | prmt5 inhibitors that cooperate with mta | |
| IL277006A (en) | CD73 inhibitors | |
| IL304348A (en) | cd73 inhibitors | |
| IL279952A (en) | Triazole glycolate oxidase inhibitors | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| IL289914A (en) | enzyme inhibitors | |
| EP4051688A4 (en) | CD73 INHIBITORS | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL289863A (en) | enzyme inhibitors | |
| IL290087A (en) | inhibitory substances | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL289783A (en) | enzyme inhibitors | |
| IL289778A (en) | enzyme inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| EP4081199A4 (en) | LIPOXYGENASE INHIBITORS | |
| GB201905328D0 (en) | Inhibitor compounds | |
| EP3768256A4 (en) | PANTROPIC ENTRY INHIBITORS | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| IL291456A (en) | Growth retarder | |
| GB201812462D0 (en) | Inhibitors |